Project Grant R01HD120347
Award Date 9/2/26
Completion Date 4/30/31
Dollars Obligated $569K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- The National Institutes of Health Office of the Director awarded $2.693 million to the University of Wisconsin–Madison on September 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to establish an Alzheimer's disease biomarker clock in Down syndrome using positron emission tomography and plasma analytes. The research addresses the underrepresentation of individuals with Down syndrome in Alzheimer's disease therapeutic trials by characterizing biomarker progression in this...
- The National Institute of Child Health and Human Development awarded the University of Wisconsin - Madison $122,361 on January 31, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate the mechanisms of reduced neuron generation in Down syndrome. The research evaluates how an extra copy of human chromosome 21 causes reduced cortical size and neuron formation during development. The work focuses on neural progenitor cell behavior during...
- Federal Grant Award Summary The National Institutes of Health Office of the Director awarded University of Wisconsin–Madison a $1.49 million Project Grant under the Trans-NIH Research Support program (CFDA 93.310) on September 16, 2025, with a completion date of August 31, 2027. This research initiative focuses on developing and characterizing humanized mouse models to study Down syndrome immune responses, specifically addressing the immune dysregulation associated with trisomy 21. The project...
- The National Institutes of Health Office of the Director awarded University of California Irvine $6.132 million on August 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the neurobiological basis for cognitive dysfunction and dementia in aging adults with Down syndrome. The project uses spatial multi-omics techniques—combining transcriptomics, epigenomics, and proteomics—to analyze over 100 clinically characterized brain samples from individuals with Down...
- The National Institute on Aging awarded the University of Wisconsin – Madison $424,648 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate ribosome quality control defects in trisomy 21 aging. The project tests a novel hypothesis that premature aging and cellular stress in Down syndrome cells arise from defects in translational fidelity and ribosome quality control caused by chromosome amplification, rather than from specific genes on chromosome 21. The research...
- The National Institute on Aging, within the Department of Health and Human Services, awarded The Medical College of Wisconsin, Inc. $429,000 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how overexpression of human chromosome 21 (HSA21) orthologs affects neurodegeneration during aging in Caenorhabditis elegans. The project addresses variability in dementia onset among individuals with Down syndrome, which results from trisomy 21. While approximately 75...
- The National Institutes of Health Office of the Director awarded the University of New Mexico Health Sciences Center $419,375 on July 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate mechanisms of vascular dysfunction in Down syndrome. The research examines endothelial dysfunction and glycocalyx depletion in a mouse model of Down syndrome (TCMAC21 mice) to understand cardiovascular disease risk in the Down syndrome population. The study investigates how...
- The National Institutes of Health Office of the Director awarded the Trustees of Boston University $763,348 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate how the HSA21-triplicated gene HMGN1 exacerbates neuropathological features in Down syndrome and Down syndrome-associated Alzheimer's disease. The research will examine HMGN1's dual mechanisms: its role as a nucleosome binding factor that facilitates chromatin accessibility and regulates genes...
- The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...